TY - JOUR
T1 - The third national Japanese antimicrobial susceptibility pattern surveillance program
T2 - Bacterial isolates from complicated urinary tract infection patients
AU - Kobayashi, Kanao
AU - Yamamoto, Shingo
AU - Takahashi, Satoshi
AU - Ishikawa, Kiyohito
AU - Yasuda, Mitsuru
AU - Wada, Koichiro
AU - Hamasuna, Ryoichi
AU - Hayami, Hiroshi
AU - Minamitani, Shinichi
AU - Matsumoto, Tetsuya
AU - Kiyota, Hiroshi
AU - Tateda, Kazuhiro
AU - Sato, Junko
AU - Hanaki, Hideaki
AU - Masumori, Naoya
AU - Hiyama, Yoshiki
AU - Yamada, Hiroki
AU - Egawa, Shin
AU - Kimura, Takahiro
AU - Nishiyama, Hiroyuki
AU - Miyazaki, Jun
AU - Matsumoto, Kazumasa
AU - Homma, Yukio
AU - Kamei, Jun
AU - Fujimoto, Kiyohide
AU - Torimoto, Kazumasa
AU - Tanaka, Kazushi
AU - Togo, Yoshikazu
AU - Uehara, Shinya
AU - Matsubara, Akio
AU - Shoji, Koichi
AU - Goto, Hirokazu
AU - Komeda, Hisao
AU - Ito, Toru
AU - Mori, Katsuhisa
AU - Mita, Koji
AU - Kato, Masao
AU - Fujimoto, Yoshinori
AU - Masue, Takako
AU - Inatomi, Hisato
AU - Takahashi, Yoshito
AU - Ishihara, Satoshi
AU - Nishimura, Kazuo
AU - Mitsumori, Kenji
AU - Ito, Noriyuki
AU - Kanamaru, Sojun
AU - Yamada, Daisuke
AU - Hiroshi, Maeda
AU - Yamashita, Masuo
AU - Tsugawa, Masaya
AU - Takenaka, Tadasu
AU - Takahashi, Koichi
AU - Oka, Yasuhiko
AU - Yasufuku, Tomihiko
AU - Watanabe, Shuji
AU - Chihara, Yoshitomo
AU - Okumura, Kazuhiro
AU - Kawanishi, Hiroaki
AU - Matsukawa, Masanori
AU - Shigeta, Masanobu
AU - Koda, Shuntaro
N1 - Funding Information:
Hiroyuki Nishiyama has received speaker's honorarium from MSD K.K., AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd. and Astellas Pharma Inc., research funding from Astellas Pharma Inc., Ono Pharmaceutical Co., Ltd. and Chugai Pharmaceutical Co., Ltd., and scholarship donations from Astellas Pharma Inc., Novartis Pharma K.K., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd. and Ono Pharmaceutical Co., Ltd.
Funding Information:
Kazuhiro Tateda received speaker honoraria from Pfizer Japan Inc., MSD K.K., Sumitomo Dainippon Pharma Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd. and Meiji Seika Pharma Co., Ltd., research funding from Meiji Seika Pharma Co., Ltd., Nippon Becton Dickinson Company, Ltd., Asahi Kasei Pharma Corporation, Eidia Co., Ltd., Eiken Chemical Co. Ltd., Nissui Pharmaceutical Co., Ltd., Spero OpCo, Inc., Shimadzu Corporation, Hitachi Ltd., Kyorin Pharmaceutical Co., Ltd., MSD K.K., Denka Company Limited, KD-ICONS Co. Ltd., and grant support from Taisho Toyama Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Asahi Kasei Pharma Corporation, Shionogi & Co., Ltd., Meiji Seika Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Pfizer Japan Inc., Astellas Pharma Inc., and FUJIFILM Toyama Chemical Co., Ltd., and scholarship donations from Taisho Toyama Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Asahi Kasei Pharma Corporation, Shionogi & Co., Ltd., Meiji Seika Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Pfizer Japan Inc., Astellas Pharma Inc. and FUJIFILM Toyama Chemical Co., Ltd., and has an endowed department sponsored by Meiji Seika Pharma Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Astellas Pharma Inc., Taisho Toyama Pharmaceutical Co., Ltd., MSD K.K. and Daiichi Sankyo Co., Ltd.
Funding Information:
This investigation was supported by grants from following pharmaceutical companies (alphabetical order): Astellas Pharma Inc. , Chugai Pharmaceutical , Daiichi-Sankyo , Daito Pharmaceutical Co., Ltd. , Fujifilm Pharma Co., Ltd. GlaxoSmithKline . K. K., Kobayashi Kako Co., Ltd. , Kyorin Pharmaceutical Co., Ltd. , Maruho Co., Ltd. , Meiji Seika Pharma , MSD K.K., Nichi-Iko Pharmaceutical Co., Ltd. , Nihon Pharmaceutical Co., Ltd. , Nipro Corporation , Ohara Pharmaceutical Co., Ltd. , Pfizer Japan , Sawai Pharmaceutical Co., Ltd. , Shionogi , Sumitomo Dainippon Pharma Co., Ltd. , Taiho Pharmaceutical , Taisho Pharmaceutical Co., Ltd. , Takata Pharmaceutical Co., Ltd. , Takeda Pharmaceutical Co., Ltd. , Tatsumi Kagaku Co., Ltd. , Towa Pharmaceutical Co., Ltd. , Toyama Chemical Co., Ltd. and Yoshindo Inc . We are grateful to T. Nakae at the Kitasato Institute (Tokyo, Japan) for their encouragements on microbiological testing and Y. Suzuki, H. Endo, and Y. Matsui for their technical assistance in this surveillance.
Funding Information:
Shingo Yamamoto has received speaker's honorarium from Daiichi Sankyo Co., Ltd., and scholarship donations from Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd, Pfizer Japan Inc., and Bayer Yakuhin, Ltd.
Funding Information:
This investigation was supported by grants from following pharmaceutical companies (alphabetical order): Astellas Pharma Inc., Chugai Pharmaceutical, Daiichi-Sankyo, Daito Pharmaceutical Co. Ltd., Fujifilm Pharma Co. Ltd. GlaxoSmithKline. K. K. Kobayashi Kako Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Maruho Co. Ltd., Meiji Seika Pharma, MSD K.K. Nichi-Iko Pharmaceutical Co. Ltd., Nihon Pharmaceutical Co. Ltd., Nipro Corporation, Ohara Pharmaceutical Co. Ltd., Pfizer Japan, Sawai Pharmaceutical Co. Ltd., Shionogi, Sumitomo Dainippon Pharma Co. Ltd., Taiho Pharmaceutical, Taisho Pharmaceutical Co. Ltd., Takata Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Tatsumi Kagaku Co. Ltd., Towa Pharmaceutical Co. Ltd., Toyama Chemical Co. Ltd. and Yoshindo Inc. We are grateful to T. Nakae at the Kitasato Institute (Tokyo, Japan) for their encouragements on microbiological testing and Y. Suzuki, H. Endo, and Y. Matsui for their technical assistance in this surveillance.
Publisher Copyright:
© 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases
PY - 2020/5
Y1 - 2020/5
N2 - The antimicrobial susceptibility patterns of bacterial pathogens isolated from patients with complicated urinary tract infections were analyzed using national surveillance data. The data consisted of 881 bacterial strains from eight clinically relevant species. The data were collected for the third national surveillance project from January 2015 to March 2016 by the Japanese Society of Chemotherapy, the Japanese Association for Infectious Disease, and the Japanese Society of Clinical Microbiology. Surveillance was undertaken with the cooperation of 41 medical institutions throughout Japan. Fluoroquinolone required a MIC90 of 2–64 mg/L to inhibit the 325 Escherichia coli strains tested and the proportion of levofloxacin resistant E. coli strains increased to 38.5% from 29.6% in 2011 and 28.6% in 2008. The proportion of levofloxacin resistant strains of Pseudomonas aeruginosa and Enterococcus faecalis decreased from previous reports and the proportion of multidrug-resistant P. aeruginosa and carbapenem-resistant Enterobacteriaceae remained low. Among methicillin-resistant Staphylococcus aureus (MRSA) strains, strains with reduced susceptibility to vancomycin (minimum inhibitory concentration, 2 μg/mL) increased to 14.7% from 5.5%. Bacterial strains that produced extended-spectrum β-lactamase included E. coli (79 of 325 strains, 24.3%), Klebsiella pneumoniae (9 of 177 strains, 7.7%), and Proteus mirabilis (6 of 55 strains, 10.9%). The proportion of extended-spectrum β-lactamase producing E. coli and K. pneumoniae strains increased from previous surveillance reports.
AB - The antimicrobial susceptibility patterns of bacterial pathogens isolated from patients with complicated urinary tract infections were analyzed using national surveillance data. The data consisted of 881 bacterial strains from eight clinically relevant species. The data were collected for the third national surveillance project from January 2015 to March 2016 by the Japanese Society of Chemotherapy, the Japanese Association for Infectious Disease, and the Japanese Society of Clinical Microbiology. Surveillance was undertaken with the cooperation of 41 medical institutions throughout Japan. Fluoroquinolone required a MIC90 of 2–64 mg/L to inhibit the 325 Escherichia coli strains tested and the proportion of levofloxacin resistant E. coli strains increased to 38.5% from 29.6% in 2011 and 28.6% in 2008. The proportion of levofloxacin resistant strains of Pseudomonas aeruginosa and Enterococcus faecalis decreased from previous reports and the proportion of multidrug-resistant P. aeruginosa and carbapenem-resistant Enterobacteriaceae remained low. Among methicillin-resistant Staphylococcus aureus (MRSA) strains, strains with reduced susceptibility to vancomycin (minimum inhibitory concentration, 2 μg/mL) increased to 14.7% from 5.5%. Bacterial strains that produced extended-spectrum β-lactamase included E. coli (79 of 325 strains, 24.3%), Klebsiella pneumoniae (9 of 177 strains, 7.7%), and Proteus mirabilis (6 of 55 strains, 10.9%). The proportion of extended-spectrum β-lactamase producing E. coli and K. pneumoniae strains increased from previous surveillance reports.
KW - Antimicrobial susceptibility
KW - Complicated urinary tract infection
KW - Minimum inhibitory concentration
KW - Surveillance
UR - http://www.scopus.com/inward/record.url?scp=85079675107&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079675107&partnerID=8YFLogxK
U2 - 10.1016/j.jiac.2020.01.004
DO - 10.1016/j.jiac.2020.01.004
M3 - Article
C2 - 32081647
AN - SCOPUS:85079675107
SN - 1341-321X
VL - 26
SP - 418
EP - 428
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
IS - 5
ER -